argenx SE

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: NL0010832176
  • BRU: ARGX
EUR
845.20
10.4 (1.25%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

55.35 k

Shareholding (Jun 2026)

FII

0.01%

Held by 2 FIIs

DII

99.99%

Held by 0 DIIs

Promoter

0.00%

iScoreScore

Dashboard

1

Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 2.90%

  • Poor long term growth as Operating profit has grown by an annual rate 31.00% of over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -227.81
2

With ROE of 18.15%, it has a Very Expensive valuation with a 7.88 Price to Book Value

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 53,515 Million ()

stock-summary
P/E

43.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.61

stock-summary
Return on Equity

19.97%

stock-summary
Price to Book

7.27

Revenue and Profits:
Net Sales:
2 Million
(Quarterly Results - Sep 2014)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
8.11%
0%
8.11%
6 Months
40.59%
0%
40.59%
1 Year
40.12%
0%
40.12%
2 Years
74.23%
0%
74.23%
3 Years
77.12%
0%
77.12%
4 Years
137.28%
0%
137.28%
5 Years
221.49%
0%
221.49%

argenx SE for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
148.85%
EBIT Growth (5y)
31.00%
EBIT to Interest (avg)
-73.64
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.61
Sales to Capital Employed (avg)
0.35
Tax Ratio
1.83%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.01%
ROCE (avg)
12.99%
ROE (avg)
2.90%

Valuation key factors

Factor
Value
P/E Ratio
43
Industry P/E
Price to Book Value
7.88
EV to EBIT
53.39
EV to EBITDA
51.87
EV to Capital Employed
18.40
EV to Sales
12.39
PEG Ratio
0.98
Dividend Yield
NA
ROCE (Latest)
34.47%
ROE (Latest)
18.15%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Bullish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 2 Foreign Institutions (0.01%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by argenx SE"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 81.76% vs 78.51% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 48.66% vs 382.19% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3,680.30",
          "val2": "2,024.80",
          "chgp": "81.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "902.70",
          "val2": "-42.90",
          "chgp": "2,204.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.60",
          "val2": "2.30",
          "chgp": "56.52%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "10.30",
          "val2": "20.90",
          "chgp": "-50.72%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,144.80",
          "val2": "770.10",
          "chgp": "48.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "238.50%",
          "val2": "-29.20%",
          "chgp": "26.77%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
3,680.30
2,024.80
81.76%
Operating Profit (PBDIT) excl Other Income
902.70
-42.90
2,204.20%
Interest
3.60
2.30
56.52%
Exceptional Items
10.30
20.90
-50.72%
Consolidate Net Profit
1,144.80
770.10
48.66%
Operating Profit Margin (Excl OI)
238.50%
-29.20%
26.77%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is 81.76% vs 78.51% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 48.66% vs 382.19% in Dec 2024

stock-summaryCompany CV
About argenx SE stock-summary
stock-summary
argenx SE
Pharmaceuticals & Biotechnology
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.
Company Coordinates stock-summary
Company Details
Willemstraat 5 , BREDA None : 4811 AH
stock-summary
Tel: 31 76 3030488
stock-summary
stock-summary
Registrar Details
Footer loading